Johnson & Johnson Stock Upgraded Despite $8 Billion Risperdal Verdict: What You Need to Know

Johnson & Johnson (NYSE: JNJ) is a massive medical products conglomerate. But skimming through the headlines it's been producing lately, you'd almost think it was a law firm -- a really bad law firm, that loses a lot of cases:

Headlines like these are part of the reason that Johnson & Johnson stock has lagged the S&P 500 by more than 10 percentage points over the past year, and is now valued at a discount to the rest of the S&P 500. And yet, one analyst believes there's still hope for Johnson & Johnson stock to outperform.

Image source: Getty Images.

Continue reading

Source Fool.com